FDA layoffs put drug and device review deadlines at risk
Delays create costs for patients awaiting products and firms financing development while regulatory clocks run.
Entities and roles
- Robert F. Kennedy Jr.Trump-appointed health and human services secretary
- Elon MuskTrump-appointed senior adviser who led DOGE work
- Donald J. Trumppresident authorizing the administration action
- Food and Drug Administrationregulator responsible for product-review deadlines
Relationships in this file
- Elon Muskcut staff needed to complete drug and device reviewsFood and Drug Administration
- Donald J. TrumpTrump-appointed health and human services secretaryRobert F. Kennedy Jr.
- Donald J. TrumpTrump-appointed senior adviser who led DOGE workElon Musk
Claims and evidence
- factreported
Reuters reported that FDA staff were struggling to meet drug and medical-device review deadlines after DOGE layoffs removed support and review personnel, creating approval uncertainty for patients and manufacturers.
- Reuters: FDA staff struggle to meet product review deadlines after DOGE layoffsPassages and source records documenting: FDA layoffs put drug and device review deadlines at risk
- factdocumented
Robert F. Kennedy Jr. was the Trump-appointed health and human services secretary.
- U.S. Department of Health and Human Services: Robert F. Kennedy, Jr.Appointment or biography record identifying Robert F. Kennedy Jr. as Trump-appointed health and human services secretary
- factdocumented
Elon Musk was the Trump-appointed senior adviser who led DOGE work.
- The White House: President Trump participates in a press conference with departing DOGE adviser Elon MuskAppointment or biography record identifying Elon Musk as Trump-appointed senior adviser who led DOGE work